Global Acute Care Syndromic Testing Research 2025, Forecast To 2034
26 Mar, 2025
How Has the Acute Care Syndromic Testing Market Size Evolved in Recent Years?
The acute care syndromic testing market has seen considerable growth due to a variety of factors.
• The market size for acute care syndromic testing has seen a rapid expansion in the recent past. It is projected to rise from $4.08 billion in 2024 to $4.62 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.2%.
Factors contributing to the historic period growth include greater awareness regarding antimicrobial resistance, escalated government funding for infectious diseases, elevated investments in healthcare infrastructure, amplified focus on syndromic testing, growth in telemedicine and an upsurge in infectious disease incidents.
What are the Market Size and Expected Growth Rates for the Acute Care Syndromic Testing Market?
The acute care syndromic testing market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for acute care syndromic testing is predicted to undergo swift expansion in the upcoming years, escalating to a projection of $7.50 billion in 2029 with a compound annual growth rate (CAGR) of 12.9%.
This expected surge during the forecast duration can be tied to increasing instances of infectious diseases, augmented need for quicker diagnostic methods, development of healthcare services, increasing utilization of multiplex syndromic panels, and the growth of the elderly population segment. The future trends within this period involve a transition to point-of-care testing, the incorporation of cloud-based platforms, the employment of multiplex panels, the creation of AI-enabled tools, and the automation of syndromic testing processes.
Which Key Drivers Are Propelling The Acute Care Syndromic Testing Market's Growth?
The acute care syndromic testing market is expected to be driven by the escalating prevalence of infectious diseases. These diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, can be communicated from one person to another, from animals, or the environment. Factors such as population expansion, urbanization, global travel, resistance to antimicrobial drugs, and climate change are driving the increase in infectious diseases, thereby elevating the demand for effective prevention and treatments. Acute care syndromic testing is key in managing infectious diseases as it allows for swift identification of pathogens and co-infections via multiplex molecular diagnostics. This facilitates precise treatment decision-making. For example, the Health Security Agency, a UK-based government entity, reported in February 2024, that the influenza positivity rate saw a hike up to 16.6% in week 4 of 2024, a rise from 14.0% the prior week. The rate of Influenza-like Illness (ILI) consultations also escalated, reaching 9.8 per 100,000 individuals, relative to 7.5 per 100,000 the prior week. Moreover, hospitalizations due to influenza saw an increase to 7.63 per 100,000, up from 5.12 per 100,000 the preceding week. Hence, the increasing prevalence of infectious diseases is fueling the growth of the acute care syndromic testing market.
What Are The Key Segments Within The Global Acute Care Syndromic Testing Market?
The acute care syndromic testing market covered in this report is segmented –
1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types
2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types
3) By Target: Bacteria, Viruses, Fungi, Parasites
4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users
Subsegments:
1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases
2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases
3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases
4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases
5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases
How Are New Trends Impacting The Size Of The Acute Care Syndromic Testing Market?
Leading businesses in the acute care syndromic testing market are prioritizing technological enhancements such as multiplex real-time polymerase chain reaction (PCR) technology. This move aims to boost diagnostic precision, permit quick identification of pathogens, simplify lab processes, lessen the response time, and elevate patient outcomes through accurate and on-time treatment strategies. Multiplex real-time PCR technology, a cutting-edge molecular diagnostic tool, simultaneously identifies and measures numerous pathogens or genetic targets in a single PCR reaction, heightening efficiency and correctness in disease diagnosis. Taking the example from April 2023, QIAGEN N.V., a biotechnological research company based in the Netherlands, debuted its QIAstat-Dx syndromic testing solution in Japan. This solution features a SARS-CoV-2 respiratory panel that can detect more than 20 pathogens from a single sample. Applying multiplex real-time PCR technology, it provides quick results with less labor relative to individual PCR tests. By 2022's end, more than 3,500 systems were globally set up, aiding the diagnosis of conditions related to respiration, gastrointestinal, and meningitis. Available in over 100 countries, the system improves syndromic testing accessibility around the globe.
Who Are the Key Players In The Acute Care Syndromic Testing Market?
Major companies operating in the acute care syndromic testing market are:
• Siemens Healthineers AG
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Becton
• Dickinson and Company
• Seegene Inc.
• bioMérieux SA
• Sysmex Corporation
• Bio-Rad Laboratories Inc.
• QIAGEN N.V.
• Werfen
• DiaSorin S.p.A.
• Quidel Corporation
• Luminex Corporation
• Biocartis NV
• Microbiologics Inc.
• QuantuMDx Group Ltd.
• Curetis GmbH by OpGen Inc.
• Genetic Signatures Ltd.
• Applied BioCode Inc.
What Are The Regional Insights Into The Acute Care Syndromic Testing Market?
North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in the acute care syndromic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.